New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety & Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Press/Media

Period18 Feb 2025

Media coverage

1

Media coverage

  • TitleNew Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety & Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date18/02/25
    PersonsMark Lebwohl
View all 1
View less